Skip to content
naulon
Not checkedNot checked for notices yet.

Bactoblis® (Streptococcus salivarius K12) — innovative therapy and prevention of acute respiratory infections and their complications

S.A. Kramarev, V.V. Yevtushenko

Aktualʹnaâ Infektologiâ · 2020

doi:10.22141/2312-413x.8.1.2020.196172 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The action of Streptococcus salivarius K12 (Bacto­blis®) is due to the colonization of the oral cavity and nasopha­rynx, that is, it is a respiratory probiotic. Streptococcus saliva­rius K12 actively inhibits the growth of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae and Mora­xella catarrhalis, which are among the main etiological factors of bacterial infections of the respiratory tract in children. Clinical studies are reviewed, their results confirm the efficacy and safety of Bactoblis® in the pediatric population with recurrent streptococcal infections of the upper respiratory tract. It emphasizes the importance of Streptococcus salivarius K12 admi­nistration after taking antibiotic therapy to restore the natural microbiocenosis of the oral cavity, nasopharynx, and to reduce antibiotic resistance.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.